SCHEMBL2235517

SCHEMBL2235517

Cc1ccccc1OS(=O)(=O)c1ccc(N2CCCNC2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
LMNA P02545 3/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR6 P50406 5/20 0.37
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
THRB P10828 1/20 0.37
HSD11B1 P28845 1/20 0.34
HSD17B3 P37058 1/20 0.34
CYP1A1 P04798 1/20 0.34
VDR P11473 1/20 0.34
ESR1 P03372 1/20 0.34
GAA P10253 1/20 0.34
ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12353646 0.94 LMNA (0.41) MAPTMEN1KMT2ALMNAHPGD
SCHEMBL2235316 0.86 DHODH (0.45) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL2233885 0.86 ALDH1A1 (0.39) MAPTLMNAHPGDALDH1A1SMN1; SMN2
SCHEMBL2302840 0.84 HTR6 (0.45) MEN1KMT2AALDH1A1SMN1; SMN2HTR6
SCHEMBL2239960 0.83 DHODH (0.40) MAPTMEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL14217358 0.82 CYP1A1 (0.37) KMT2ALMNAHTR6THRBCYP1A1
SCHEMBL2303210 0.81 ALDH1A1 (0.48) MAPTLMNAL3MBTL1ALDH1A1CYP1A1
SCHEMBL2237141 0.81 SMN1; SMN2 (0.53) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL2301814 0.80 LMNA (0.39) MAPTMEN1KMT2ALMNAHPGD
SCHEMBL2305210 0.80 DHODH (0.47) MAPTMEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 MAPT 4618/4885MEN1 1673/4885KMT2A 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.